Role of Turmeric on Oxidative Modulation in ESRD Patients
Raktažodžiai
Santrauka
apibūdinimas
End-stage renal disease (ESRD) is a state of oxidative stress, due to uremic oxidant mediator's accumulation, the activation of phagocytic oxidative metabolism by the dialysis membrane, intravenous iron therapy and the antioxidant depletion caused by hemodialysis (HD). Some trials showed a significant benefit from antioxidant therapy on cardiovascular outcome in HD patients.
Extensive research focused on direct exogenous antioxidants including vitamin C, and vitamin E, in the treatment of cardiovascular disease. Some clinical trials showed no more beneficial effect of exogenous antioxidant supplementation in cardiovascular disease (CVD) and recommended the necessity for a new approach to regulating cellular redox status.
Turmeric (Curcuma longa Linn) is an herb used as a dietary spice and in traditional medicine for centuries. Curcumin, the most active and non-toxic component of turmeric, is a polyphenol, which has been extensively studied for its therapeutic benefits, such as antioxidant. Besides, turmeric has also been effective in attenuation of proteinurea in diabetic nephropathy and lupus nephritis patients.
Curcumin restored the activities of mitochondrial enzymes complexes and thereby attenuated the release of reactive oxygen species. Turmeric appears to be non-toxic to humans even at high doses. However, there is a paucity of information on the effect of turmeric in HD population. We have, therefore, followed up this study to determine the beneficial effect of turmeric on oxidative stress in HD patients.
Datos
| Paskutinį kartą patikrinta: | 06/30/2013 |
| Pirmasis pateikimas: | 07/20/2013 |
| Numatytas registravimas pateiktas: | 07/22/2013 |
| Pirmas paskelbtas: | 07/23/2013 |
| Paskutinis atnaujinimas pateiktas: | 07/22/2013 |
| Paskutinis atnaujinimas paskelbtas: | 07/23/2013 |
| Faktinė studijų pradžios data: | 03/31/2011 |
| Numatoma pirminio užbaigimo data: | 07/31/2012 |
| Numatoma studijų užbaigimo data: | 07/31/2012 |
Būklė ar liga
Intervencija / gydymas
Drug: drug: turmeric capsule
Drug: Drug: placebo,capsule
Fazė
Rankų grupės
| Ranka | Intervencija / gydymas |
|---|---|
| Experimental: drug: turmeric capsule Intervention is turmeric (one capsule with each meal containing 500 mg turmeric, of which 22.1 mg was the active ingredient curcumin; three capsules daily) for 8 weeks | Drug: drug: turmeric capsule |
| Placebo Comparator: Drug: placebo,capsule Intervention is daily starch capsules 500 mg for 8 weeks | Drug: Drug: placebo,capsule |
Tinkamumo kriterijai
| Amžius, tinkami studijuoti | 18 Years Į 18 Years |
| Tinkamos studijoms lytys | All |
| Priima sveikus savanorius | Taip |
| Kriterijai | Inclusion Criteria: - having the age of 18 years and more, - receiving 4-hour HD treatments 3 times per week at least for three months, - administering no other antioxidant medications Exclusion Criteria: |
Rezultatas
Pirminės rezultatų priemonės
1. effects of turmeric on oxidative stress markers [8 weeks]
